NO140977C - Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner

Info

Publication number
NO140977C
NO140977C NO884/73A NO88473A NO140977C NO 140977 C NO140977 C NO 140977C NO 884/73 A NO884/73 A NO 884/73A NO 88473 A NO88473 A NO 88473A NO 140977 C NO140977 C NO 140977C
Authority
NO
Norway
Prior art keywords
dihydropyridines
amino
preparation
therapeutic active
analogical procedure
Prior art date
Application number
NO884/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO140977B (no
Inventor
Horst Meyer
Friedrich Bossert
Wulf Vater
Kurt Stoepel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO140977B publication Critical patent/NO140977B/no
Publication of NO140977C publication Critical patent/NO140977C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
NO884/73A 1972-03-06 1973-03-05 Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner NO140977C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2210674A DE2210674C3 (de) 1972-03-06 1972-03-06 2-Amino-6-methyl-1,4-dihydropyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
NO140977B NO140977B (no) 1979-09-10
NO140977C true NO140977C (no) 1979-12-19

Family

ID=5838026

Family Applications (1)

Application Number Title Priority Date Filing Date
NO884/73A NO140977C (no) 1972-03-06 1973-03-05 Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner

Country Status (27)

Country Link
US (1) US3867393A (pl)
JP (2) JPS5720306B2 (pl)
AT (1) AT324337B (pl)
AU (1) AU468090B2 (pl)
BE (1) BE796278A (pl)
BG (1) BG23213A3 (pl)
CA (1) CA983033A (pl)
CH (1) CH580590A5 (pl)
DD (1) DD107274A5 (pl)
DE (1) DE2210674C3 (pl)
DK (1) DK136214C (pl)
ES (1) ES412322A1 (pl)
FI (1) FI56681C (pl)
FR (1) FR2183675B1 (pl)
GB (1) GB1369401A (pl)
HK (1) HK44977A (pl)
HU (1) HU167087B (pl)
IE (1) IE37369B1 (pl)
IL (1) IL41665A (pl)
LU (1) LU67148A1 (pl)
NL (1) NL7303136A (pl)
NO (1) NO140977C (pl)
PL (1) PL89258B1 (pl)
RO (1) RO61193A (pl)
SE (1) SE384207B (pl)
YU (1) YU44873A (pl)
ZA (1) ZA731503B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959296A (en) * 1972-06-10 1976-05-25 Bayer Aktiengesellschaft 1,4-Dihydropyridines
US3974278A (en) * 1973-07-12 1976-08-10 Bayer Aktiengesellschaft 1,4-Dihydropyridine esters
CH607848A5 (pl) * 1974-06-04 1978-11-30 Bayer Ag
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
DE2715182A1 (de) * 1977-04-05 1978-10-19 Bayer Ag 2-alkylenaminodihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
FI813460L (fi) * 1980-11-10 1982-05-11 Sandoz Ag Nya 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-pyridinderivat deras framstaellningsfoerfarande och dessa innehaollande farmaceutiska kompositioner
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
US4603135A (en) * 1983-10-17 1986-07-29 Takeda Chemical Industries, Ltd. Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates
GB8620880D0 (en) * 1986-08-29 1986-10-08 Pfizer Ltd Therapeutic agents
US4912239A (en) * 1987-11-13 1990-03-27 Dow Corning Corporation Method for stabilizing unsaturated organosilicone compositions
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
DE4430095A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 6-Amino-1,4-dihydropyridinen als Arzneimittel zur Behandlung des zentralen Nervensystems und Verfahren zu ihrer Herstellung
DE4444860A1 (de) * 1994-12-16 1996-06-20 Bayer Ag Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
WO2005025507A2 (en) * 2003-09-10 2005-03-24 Synta Phamaceuticals Corp. Dihydropyridine compounds for treating or preventing metabolic disorders
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325505A (en) * 1965-02-24 1967-06-13 Smith Kline French Lab 4-cycloalkyl(or cycloalkenyl)-dihydropyridines
US3511847A (en) * 1967-02-07 1970-05-12 Smithkline Corp 2,6-di-lower alkyl - 1,4-dihydro - 4-(2-trifluoromethylphenyl) - 3,5 - pyridinedicarboxylic acid esters
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE2013431C3 (de) * 1970-03-20 1979-12-20 Bayer Ag, 5090 Leverkusen 4-Azidophenyl-l,4-dihydropyridin-3,5-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
ZA7152B (en) * 1970-01-24 1971-10-27 Bayer Ag New pharmaceutically active 1,4-dihydropyridines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
FR2183675A1 (pl) 1973-12-21
IL41665A (en) 1975-08-31
DK136214B (da) 1977-09-05
DE2210674C3 (de) 1981-09-24
CA983033A (en) 1976-02-03
BG23213A3 (bg) 1977-07-12
GB1369401A (en) 1974-10-09
BE796278A (fr) 1973-09-05
FR2183675B1 (pl) 1976-12-03
AT324337B (de) 1975-08-25
CH580590A5 (pl) 1976-10-15
ZA731503B (en) 1973-11-28
NL7303136A (pl) 1973-09-10
JPS5798265A (en) 1982-06-18
DE2210674A1 (de) 1973-09-13
JPS5720306B2 (pl) 1982-04-27
RO61193A (pl) 1976-10-15
HK44977A (en) 1977-09-09
IE37369B1 (en) 1977-07-06
PL89258B1 (pl) 1976-11-30
NO140977B (no) 1979-09-10
DK136214C (da) 1978-03-06
AU468090B2 (en) 1975-03-27
DD107274A5 (pl) 1974-07-20
US3867393A (en) 1975-02-18
FI56681B (fi) 1979-11-30
IE37369L (en) 1973-09-06
AU5287573A (en) 1975-03-27
DE2210674B2 (de) 1980-09-04
HU167087B (pl) 1975-08-28
YU44873A (en) 1982-02-25
FI56681C (fi) 1980-03-10
IL41665A0 (en) 1973-05-31
JPS48103586A (pl) 1973-12-25
ES412322A1 (es) 1976-01-01
LU67148A1 (pl) 1973-05-22
SE384207B (sv) 1976-04-26

Similar Documents

Publication Publication Date Title
NO140381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arylpiperaziner
NO139560C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
NO145382C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-amino-indazolkarboksylsyrederivater.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
NO141800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO143460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO138565C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinyl-propyl-1,2,4-triazolinonderivater
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO140977C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner
NO140058C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte piperidinoalkanol-oxim-derivater
NO138999C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive difenylyl-alkanoylaminopyridiner
NO137899C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n (1h-tetrazol-5-yl)-kinaldamider
NO138599C (no) Analogifremgangsmaate til fremstilling av nye, terapeutisk virksomme tienopyrimidinderivater
NO141850C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolderivater.
NO137858C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indanoner
NO139088C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2beta,16beta-diamino-5alfa-androstaner
NO138025C (no) Analogifremgangsmaate til fremstilling av antimykotisk virksomme 1-etyl-imidazoler
NO137728C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrasi-4-oksyd-derivater
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
NO136574C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrimidinderivater.
NO138251C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzylaminer
NO136840C (no) Analogifremgangsm}te til fremstilling av nye, terapeutisk aktive derivater av isoindolin
NO140299C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-aryl-5-aminoalkyl-4-oksazolin-2-oner
NO140104C (no) Analogifremgangsmaate til fremstilling av 17beta-hydroksy-16,16-dimetylestr-4-en-3-on med terapeutisk aktivitet
NO138568C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 21-(bea-benzoylaminoisobutyryl)-16alfa,17alfa-(p-dimethyl-aminobenzyliden)-triamcinolon